27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Moderna, Inc.'s (NASDAQ:MRNA) vaccine franchise has further legs to play out, according to an analyst at Morgan Stanley.
The Moderna Analyst: Matthew Harrison has an Equal-weight rating and a $313 price target for Moderna shares.
The Moderna Thesis: The success of COVID-19 mRNA vaccines has led to the development of additional respiratory vaccines using the technology, Harrison said in a note.
Related Link: Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The next key vaccine readout, the analyst said, will be on Moderna's lead flu candidate, code-named mRNA-1010, in the coming weeks to months.
Current flu vaccines suffer from relatively low efficacy, evident in low antibody titers, and a mismatch of encoded antigens to flu proteins circulating during the season, the analyst said. Based on Morgan Stanley's modeling, a mean HAI titer of about 1,500 would translate to a 90% effective vaccine.
A highly effective vaccine can have seroconversion rates above the 50-60% from current flu vaccines, the analyst said.
"We believe Moderna can achieve this threshold, which should increase investor confidence in the LT vaccine franchise," the analyst wrote in the note.
MRNA Price Action: Moderna shares closed down 0.34% at $234.28
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!